Search research articles
Contact Us
Filters
Showing results (181-190 of 188) with videos related to
Page
of 19
Sort By:
You have reached the last page of results.
This site can display upto 188 results.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Nature Medicine
|
October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd, Ross L Levine, Amy S Ruppert, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Leukemia & Lymphoma
|
September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemia
Leslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Cancer
|
April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Vu H Duong, Amy S Ruppert, Alice S Mims, et al.
Physical Review Letters
|
April 7, 2025
ADMX Axion Dark Matter Bounds around 3.3 μeV with Dine-Fischler-Srednicki-Zhitnitsky Discovery Ability
C Goodman, M Guzzetti, C Hanretty, et al.
Physical Review Letters
|
November 21, 2025
Search for Axion Dark Matter from 1.1 to 1.3 GHz with ADMX
G Carosi, C Cisneros, N Du, et al.
Page
of 19
Search research articles
Search
Showing results (181-190 of 188) with videos related to
Sort By:
Page
of 19
You have reached the last page of results.
This site can display upto 188 results.
The New England Journal of Medicine
|
July 5, 2023
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
Anthony R Mato, Jennifer A Woyach, Jennifer R Brown, et al.
Nature Medicine
|
October 27, 2020
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd, Ross L Levine, Amy S Ruppert, et al.
Haematologica
|
October 4, 2024
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
Nirav N Shah, Michael Wang, Lindsey E Roeker, et al.
The Lancet. Haematology
|
May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
M Lia Palomba, Manish R Patel, Toby A Eyre, et al.
Leukemia & Lymphoma
|
September 7, 2022
Development of a distributed international patient data registry for hairy cell leukemia
Leslie A Andritsos, Mirela Anghelina, Jasmine Neal, et al.
Cancer
|
April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Vu H Duong, Amy S Ruppert, Alice S Mims, et al.
Physical Review Letters
|
April 7, 2025
ADMX Axion Dark Matter Bounds around 3.3 μeV with Dine-Fischler-Srednicki-Zhitnitsky Discovery Ability
C Goodman, M Guzzetti, C Hanretty, et al.
Physical Review Letters
|
November 21, 2025
Search for Axion Dark Matter from 1.1 to 1.3 GHz with ADMX
G Carosi, C Cisneros, N Du, et al.
Page
of 19